Respiratory Diseases

Your daily dose of the clinical news you may have missed.

Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.

Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.

Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.

The study looked at the impact over 3 years but found that most of the averted burden, including more than 8000 fewer deaths, occur in the first year after vaccination.

The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.

The updated guidelines reflect the progress made in protecting against severe illness from COVID-19, said CDC Director Mandy Cohen, MD, MPH.

The bivalent vaccine demonstrated "durable efficacy" of more than 80% over 2 RSV seasons, according to Pfizer's report of topline findings from the RENOIR trial.

COVID-19 hospitalizations have never fall below 6000/week, according to the ACIP; those aged 65+ have the highest inpatient rate, those aged 75+ have the highest mortality.

Test your COPD IQ with these 8 questions on spirometry in COPD diagnosis, COPD exacerbations and treatment response, when to add ICS, and other topics for PCPs.

Your daily dose of the clinical news you may have missed.

AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.

Conversely, increases in physical activity of just 500 METs/mins/week reduced respiratory ED visits or hospitalizations by 10-14%, according to a Korean study.

Get GOLD Report updates at-a-glance on initiating pharmacotherapy, avoiding exacerbations, treating dyspnea, how to approach using ICS, plus other topics.

Influenza continues to rage in some parts of the US; try these 4 quick questions on vaccines you may or may not have on hand.

Updates in the Global Initiative for Obstructive Lung Disease report include using spirometry values in diagnosis and optimizing inhaled pharmacotherapy.

The combination SABA/ICS inhaler is the first of its kind and treats both acute bronchoconstriction and the inflammation that drives asthma and disease exacerbation.

The risk of asthma and poor outcomes was even greater among children with both conditions than among adults in this first study to compare the 2 populations.

Your daily dose of the clinical news you may have missed.

In persons with COPD, use of the anticonvulsants was linked to a 39% increase in risk of severe disease exacerbation requiring hospital admission, study authors reported.

Your daily dose of the clinical news you may have missed.

RSV vaccines from Pfizer-BioNTech and Moderna for adults aged 60 years and older aren't that different, so which would you recommend if a patient asks?

The risk of severe CV events, including leading to death, was greatest in the first week following an exacerbation but remained significantly elevated 1 year later.

Your daily dose of the clinical news you may have missed.

After hospital discharge, persons who had COVID-19 remained at greater risk of death and myriad adverse health outcomes compared with those who had seasonal flu.

Moderna's investigational vaccine against RSV in adults showed mean efficacy of 83% against the infection and is the only mRNA technology-based RSV shot.

Higher serum levels of the omega-3 fatty acids were associated with slowed disease progression and longer transplant-free survival in a new study.

If approved the 21-valent shot would be the first pneumococcal conjugate vaccine indicated specifically for adults.

Your daily dose of the clinical news you may have missed.

The coadministration of RSVpreF and seasonal influenza vaccine was found to generate robust immune responses in older adults, reported authors of new study.